Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
October 26 2022 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company leveraging its extensive virology
expertise to develop novel therapeutics that target specific viral
diseases, today announced that it has scheduled its third quarter
2022 financial results and corporate update for Wednesday, November
9, 2022. The schedule for the press release and conference
call/webcast are as follows:
• |
Q3/2022 Press Release: |
Wednesday, November 9, 2022 at 7:30 a.m. ET |
• |
Q3/2022 Conference Call/Webcast: |
Wednesday, November 9, 2022 at 8:45 a.m. ET |
|
|
|
To dial-in for the conference call by phone,
please register using the following link: Registration Link. A live
webcast of the conference call can be accessed through the
Investors section of Arbutus' website at
www.arbutusbio.com.
An archived webcast will be available on the
Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to develop novel therapeutics that target
specific viral diseases. Our current focus areas include Hepatitis
B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are
developing a RNAi therapeutic, an oral capsid inhibitor, an oral
PD-L1 inhibitor, and oral RNA destabilizer that we intend to
combine with the aim of providing a functional cure for patients
with chronic HBV by suppressing viral replication, reducing surface
antigen and reawakening the immune system. We believe our lead
compound, AB-729, is the only RNAi therapeutic with evidence of
immune re-awakening. It is currently being evaluated in multiple
phase 2 clinical trials. We also have an ongoing drug discovery and
development program directed to identifying novel, orally active
agents for treating coronavirus (including SARS-CoV-2). In
addition, we are exploring oncology applications for our internal
PD-L1 portfolio. For more information, visit
www.arbutusbio.com.Contact Information
Investors and Media
William H. CollierPresident and CEO Phone: 267-469-0914Email:
ir@arbutusbio.comLisa M. CaperelliVice President, Investor
RelationsPhone: 215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024